Boiron : Q3 2023 sales miss our expectations - OP growth guidance ditched for 2023 - Contribution from majority stake to Boiron Developpement
>Q3: -5.7% and -2.8% excl. Covid - Boiron published Q3 sales of € 121m, down by 5.7%, and by 2.8% excluding Covid sales. On a 9-month cumulative basis, sales were down by 6.3%, impacted by the base effect from significant Covid test sales in France over 2022. Excluding COVID tests, sales were up 3%. This growth was spilt across all geographical regions and was driven by homoeopathic specialities sales. Boiron did not provide any guidance but said the decline in test s...Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.